Publications

Detailed Information

Risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae : Risk Factors for Ciprofloxacin Resistance in Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae

DC Field Value Language
dc.contributor.authorKang, CI-
dc.contributor.authorKim, SH-
dc.contributor.authorKim, DM-
dc.contributor.authorPark, WB-
dc.contributor.authorLee, KD-
dc.contributor.authorKim, HB-
dc.contributor.authorOh, MD-
dc.contributor.authorKim, EC-
dc.contributor.authorChoe, KW-
dc.date.accessioned2024-04-26T01:14:46Z-
dc.date.available2024-04-26T01:14:46Z-
dc.date.created2023-05-01-
dc.date.issued2004-
dc.identifier.citationMicrobial Drug Resistance, Vol.10 No.1, pp.71-76-
dc.identifier.issn1076-6294-
dc.identifier.urihttps://hdl.handle.net/10371/199794-
dc.description.abstractThe present study was conducted to identify risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae (ESBL-EK). ESBL production was determined in stored E. coli and K. pneumoniae blood isolates from January, 1998, to December, 2002, by National Committee for Clinical Laboratory Standards (NCCLS) guidelines and/or double-disk synergy test. Antimicrobial susceptibility was determined by the disk diffusion test method. A total of 133 patients with ESBL-EK bacteremia were analyzed retrospectively. A total of 80 (60.2%) patients experienced bacteremia due to strains resistant to ciprofloxacin. There were no significant differences in age, sex, and APACHE II score between the ciprofloxacin-resistant group (CIP-R) and -susceptible group (CIP-S). The most common primary site of infection in CIP-R was pancreaticobiliary tract infection (46/80, 57.5%) and that in CIP-S was unknown primary site (23/53, 43.4%). Independent risk factors for ciprofloxacin resistance were: prior use of fluoroquinolones (OR, 5.53; 95% CI, 1.56-25.42, p = 0.032), indwelling urinary catheter (OR, 3.68; 95 % CI, 1.27-10.67, p = 0.017), and invasive procedure within 72 hr prior to bacteremia (OR, 4.03; 95 % CI, 1.44-11.25,p = 0.008). Our data suggest that strategies designed to reduce the ciprofloxacin resistance rate in ESBL-EK strains should focus on limiting the use of fluoroquinolones and minimizing invasive procedures, including insertion of a urinary catheter.-
dc.language영어-
dc.publisherMary Ann Liebert Inc.-
dc.titleRisk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae-
dc.title.alternativeRisk Factors for Ciprofloxacin Resistance in Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae-
dc.typeArticle-
dc.identifier.doi10.1089/107662904323047835-
dc.citation.journaltitleMicrobial Drug Resistance-
dc.identifier.wosid000221015400010-
dc.identifier.scopusid2-s2.0-1942466457-
dc.citation.endpage76-
dc.citation.number1-
dc.citation.startpage71-
dc.citation.volume10-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorPark, WB-
dc.contributor.affiliatedAuthorKim, HB-
dc.contributor.affiliatedAuthorOh, MD-
dc.contributor.affiliatedAuthorKim, EC-
dc.type.docTypeArticle; Proceedings Paper-
dc.description.journalClass1-
dc.subject.keywordPlusGRAM-NEGATIVE BACILLI-
dc.subject.keywordPlusFLUOROQUINOLONE RESISTANCE-
dc.subject.keywordPlusEMERGENCE-
dc.subject.keywordPlusCANCER-
dc.subject.keywordPlusENTEROBACTERIACEAE-
dc.subject.keywordPlusASSOCIATION-
dc.subject.keywordPlusBACTEREMIA-
dc.subject.keywordPlusTHERAPY-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Immunology, Infectious Diseases, Vaccination, 감염병, 바이러스질환, 예방접종

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share